Authors
Ze-Qing Li, Song-Yang Wu, Li-Ping Ge, Xiang-Rong Wu, Wen-Ya Wu, Cheng-Lin Liu, Zhi-Ming Shao
Published in
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Pages JCO2600261. Oct 20, 2026. Epub Oct 20, 2026.
Abstract
Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the most common subtype, lacks simple, noninvasive biomarkers for recurrence. We evaluated circulating eosinophil count as a clinically applicable biomarker for recurrence in this population.
Associations between preoperative eosinophil count and patient outcomes were evaluated in a multimodal discovery cohort (N = 472) and validated via propensity score overlap weighting in an independent expanded cohort (N = 23,170). We assessed the additive value of eosinophils in patients with 21-gene recurrence scores (RSs; n = 2,973) and their predictive role for adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in high-risk patients (n = 3,471). Mechanisms were investigated using integrated multiomics, spatial digital pathology, and in vivo preclinical models.
Higher circulating eosinophil counts correlated with significantly improved recurrence-free and distant metastasis-free survival in the discovery cohort. Genomic analysis associated these elevated counts with lower human leukocyte antigen homozygosity and increased intratumoral immune activation. Functionally, eosinophils were associated with antitumor effects, with evidence of CD8+ T-cell involvement. These findings were further validated in vivo, where eosinophil adoptive transfer significantly reduced tumor burden in both the EMT6 (BALB/c) and E0771 (C57BL/6) mouse models. Spatial profiling demonstrated that tumor-infiltrating eosinophils predominantly coaggregated with lymphocytes. These clinical associations were then validated in the independent expanded cohort through multivariable and propensity score-weighted analyses. Critically, eosinophil levels provided additive prognostic value beyond the 21-gene RS and, among high-risk patients, predicted the subset that would derive greater benefit from CDK4/6 inhibition.
Circulating eosinophil count serves as a potential clinically applicable, liquid biopsy biomarker that independently prognosticates recurrence risk and predicts CDK4/6 inhibitor benefit, reflecting systemic immune activation in hormone receptor-positive/HER2- breast cancer.
PMID:
42900864
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 28
- Comments 0